Abstract: In order to ensure communication performance, a weight measuring device 1 includes a weight measurer configured to have a measurement target object placed thereon and measure a weight of the measurement target object, a communication module configured to transmit a measurement value of the weight of the measurement target object measured by the weight measurer by wireless communication, and an arrangement unit formed in an upper part of the weight measurer, the arrangement unit being configured to have at least an antenna of the communication module disposed on an upper side of the weight measurer.

Abstract: A display device includes: a display panel including panel terminals; and a wiring substrate including first substrate terminals coupled to the panel terminals. The panel terminals include panel terminals arranged in a first region and panel terminals arranged in second regions sandwiching the first region. The first substrate terminals include first substrate terminals arranged in a third region and first substrate terminals arranged in fourth regions sandwiching the third region. A gap between panel terminals is substantially constant in the first and second regions. A first width of the panel terminals in the first region is different from a second width of the panel terminals in the second regions. A width of the first substrate terminals is substantially constant in the third and fourth regions. A first gap between first substrate terminals in the third region is different from a second gap between first substrate terminals in the fourth regions.

Abstract: The present invention relates to an ophthalmic aqueous composition containing a silver salt, and filled in a container made of a polyester-based resin, or a container made of a polyolefin-based resin excluding polypropylene. Besides, the present invention also relates to an ophthalmic preservative containing a silver salt, and filled in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene, and a method for imparting, to an ophthalmic aqueous composition, preservative efficacy satisfying a criterion of Preservatives-Effectiveness Tests of The Japanese Pharmacopoeia, including adding a silver salt to the ophthalmic aqueous composition, and filling the ophthalmic aqueous composition in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene.

Abstract: Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.

Abstract: Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (I), which is at a pH range of 6 or lower, wherein the buffer (I) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

Abstract: Provided is an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, the cationic polymer being at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt-acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soy protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, a dimethyldiacrylammonium chloride homopolymer, an adipic acid-dimethylaminohydroxypropyldiethylenetriamine copolymer, an adipic acid-epoxypropyldiethylenetriamine copolymer and an acrylamide-?-methacryloyloxyethyltrimethylammoniummethyl sulfate copolymer.

Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.

Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.

Abstract: A method and an apparatus for treating coal gasification wastewater containing selenium and ions of a metal nobler than titanium eluted from a noble metal catalyst in a catalytic wet oxidation treatment using the noble metal catalyst, the method includes a pretreatment process removing the ions of the metal nobler than titanium and a selenium reduction process contacting the coal gasification wastewater with a mixture of metallic titanium and a simple metal baser than metallic titanium whereby a portion of the simple metal baser than metallic titanium is eluted, and the selenium in the coal gasification wastewater becomes reduced.

Abstract: Selenium-containing water containing ions of a metal which is nobler than titanium and which is a coexisting substance is stably and efficiently treated. A pretreatment of removing ions of the metal nobler than titanium from the selenium-containing water is performed prior to the reduction treatment of selenium with the mixture of metallic titanium and the simple metal baser than titanium. In a reduction treatment step of selenium, noble metal ions in the selenium-containing water are reduced on the surfaces of particles of metallic titanium in a titanium/base metal mixture to form precipitates, which adhere to the surfaces of the metallic titanium particles, resulting in the decrease in efficiency of a reduction reaction. This problem can be solved in such a manner that the noble metal ions are removed prior to the reduction treatment of selenium.

Abstract: An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.

Abstract: A method and an apparatus for treating selenium-containing wastewater, in which wastewater containing hexavalent selenium is subjected to reduction treatment, selenium can be effectively removed at a small amount of metal leached, and, preferably, sludge produced during treatment is white, thereby facilitating the disposal of the sludge. The selenium-containing wastewater is brought into contact with an alloy or a mixture of metallic titanium and a first metal other than metallic titanium to partially leach the first metal, thereby subjecting selenium in the wastewater to reduction treatment.

Abstract: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.

Abstract: An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to 3); 1) adding a surfactant, 2) using benzalkonium chloride represented by the formula of [C6H5CH2N(CH3)2R]Cl (wherein R is alkyl having 12 carbon atoms) as the preservative and 3) adding a nonionic tonicity agent as a tonicity agent.

Abstract: An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.

Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.

Abstract: A method of stabilizing latanoprost in an ophthalmic solution containing 0.005% (W/V) of latanoprost to be stored to be stored at room temperature (i) by adding 0.1 to 2% (W/V) of ?-aminocaproic acid to the solution or (ii) by adding 0.1 to 2% (W/V) of ?-aminocaproic acid and adjusting the pH of the solution to 5.0 to 6.25.

Abstract: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.

Abstract: A method and an apparatus for treating selenium-containing wastewater, in which wastewater containing hexavalent selenium is subjected to reduction treatment, selenium can be effectively removed at a small amount of metal leached, and, preferably, sludge produced during treatment is white, thereby facilitating the disposal of the sludge. The selenium-containing wastewater is brought into contact with an alloy or a mixture of metallic titanium and a first metal other than metallic titanium to partially leach the first metal, thereby subjecting selenium in the wastewater to reduction treatment.

Abstract: There is provided an image reader system including an attribute acquisition unit that acquires an attribute of an original that has been detected by an image reader unit that optically reads an image of the original, and an image output unit that outputs the attribute that has been acquired by the image reader unit and image data that are acquired by the reading of the image reader unit with the attribute and the image data being associated with each other.